<h4>Background</h4>Epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma (LUAD) is the most common subtype among non-small cell lung cancer (NSCLC) and targeted therapies are the primary approach for treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.